CoChat
Sign Up
Cited by 319Sirtuins and Resveratrol in MedicineLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial

Chen, Shihui, Zhao, Xiaolan, Ran, Li, Wan, Jing, Wang, Xiaofang, Qin, Yu, Shu, Furong, Gao, Yanxiang +3 more·2015·Digestive and Liver Disease
DOI 10.1016/j.dld.2014.11.015
Open this paper in CoChat — free account

Abstract

Background Non-alcoholic fatty liver disease is a major health problem worldwide. Resveratrol is a natural polyphenol found in edible plants that has a variety of biochemical and physiological effects.Aims To evaluate the effect of resveratrol on insulin resistance, glucose and lipid metabolism in non-alcoholic fatty liver disease.Methods Double-blind, randomized, placebo-controlled trial: 60 subjects with non-alcoholic fatty liver disease were given 2 placebo capsules (placebo group) or 2 150mg resveratrol capsules (resveratrol group) twice daily for three months. Liver ultrasound imaging, anthropometric profile, serum liver enzymes, insulin, glucose, C-peptide, lipid profile, and inflammation-related cytokines were compared pre and post-treatment.Results Compared with the placebo group, resveratrol significantly decreased aspartate aminotransferase, glucose and low-density lipoprotein cholesterol [-6.00 (-9.00, -3.00) IU/L, -0.64±0.31mmol/L, and -0.41±0.35mmol/L, respectively, P≤0.001] alanine aminotransferase, total cholesterol [-7.00 (-11.0, -2.50) IU/L and -0.67±0.50mmol/L, respectively, P=0.002], and homeostasis model assessment insulin resistance index (-0.60±1.15, P=0.016). In the resveratrol group significant reductions of the levels of tumour necrosis factor-alpha, cytokeratin 18 fragment, and fibroblast growth factor 21 [-0.53±1.30pg/mL, -26.9 (-70.3, 5.12) IU/L and -23.3 (-43.0, 0.31) pg/mL, respectively, P<0.05] and elevation of adiponectin level [1.22 (-0.37, 1.60) ng/mL, P=0.025] were observed.Conclusion Resveratrol supplementation may benefit patients with non-alcoholic fatty liver disease.

Integrity signals

Registry

Crossref · 10.1016/j.dld.2014.11.015

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The antiandrogenic effects of resveratrol in PCOS women are probably indirect and driven by the reduction of insulin resistance, in contrast to pharmacologic intervention with metformin.

    “Given that chronic hyperinsulinemia can stimulate an excessive production of androgens in PCOS women, the antiandrogenic effects of resveratrol are probably indirect and driven by the reduction of IR in these patients [141,142,143,144], in contrast to pharmacologic intervention with metformin [145,146].”

    From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [142]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., Shu, F., Gao, Y., Yuan, L., Zhang, Q., & Mi, M.
Affiliations
Army Medical University (CN)
Corresponding author
  • Zhang, Qianyong
  • Mi, Mantian
ORCID
Venue
Digestive and Liver Disease
Publisher
Elsevier BV
Published
2015-03
Volume
47
Issue
3
Pages
226-232
ISSN
1590-8658 (ISSN-L)
DOI
10.1016/j.dld.2014.11.015
OpenAlex
W2074601722
Cited by
319
References
44
Citations by year
2026: 15 · 2025: 15 · 2024: 31 · 2023: 28 · 2022: 23 · 2021: 45 · 2020: 35 · 2019: 27 · 2018: 38 · 2017: 18 · 2016: 24 · 2015: 19 · 2012: 1
FWCI
10.36
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Digestive and Liver Disease (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
resveratrol, non-alcoholic fatty liver disease, insulin resistance, glucose metabolism, lipid metabolism, liver enzymes, adiponectin, TNF-α, cytokeratin-18 fragments, FGF21, polyphenol supplementation, inflammation
MeSH terms
Resveratrol, Adult, Alanine Transaminase, Aspartate Aminotransferases, Blood Glucose, Cholesterol, Double-Blind Method, Female, Homeostasis, Humans, Insulin, Insulin Resistance, Liver, Male, Middle Aged, Stilbenes, Ultrasonography, Cytokines, Lipid Metabolism, Young Adult, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review